We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Targeting the Engine Room of the Cancer Cell

News   Jun 19, 2018 | Original story from Columbia University Irving Medical Center (CUIMC)

 
Targeting the Engine Room of the Cancer Cell

The pipeline consists of a series of pre-computed (*) components, including a reference set of more than 13,000 tumor expression profiles representing 35 different tumor types, a collection of 28 tissue context-specific interactomes and a database of context-specific mechanism of action (MoA) for >400 FDA-approved drugs and investigational compounds in oncology. The transcriptome of the perturbed cell lines is profiled at low cost by PLATE-Seq. The process begins with the expression profile of a single patient sample, which is compared against the tumor databank to generate a tumor gene expression signature. This signature is interpreted by VIPER using a context-matched interactome to identify the set of most dysregulated proteins, which constitute the regulators of the tumor cell state -- tumor checkpoint. These proteins are then aligned against the drugs' and compounds' MoA database, to prioritize compounds able to invert the activity pattern of the tumor checkpoint. Credit: CUIMC/Califano Lab

 
 
 

RELATED ARTICLES

Boy With Rare Brain Tumor One of First in UK to Receive Proton Beam Therapy Treatment

News

A 15-year old from West Sussex, diagnosed with a brain tumor last August, will become one of the first patients in the UK to receive state-of-the-art proton beam therapy treatment at a new £125 million center opened in Manchester.

READ MORE

Swallowing This Special Sponge Enables Esophageal Cancer Detection

News

Swallowing a small capsule attached to a long string could be the way forward in detecting esophogeal cancer.

READ MORE

Making Resistant Melanomas Susceptible to Immunotherapy

News

A Ludwig Cancer Research study has uncovered a cellular mechanism by which melanomas that fail to respond to checkpoint blockade may be made susceptible to such immunotherapies.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE